Selection and characterization of tenascin C targeting peptide

Molecules and Cells

Volumn 33, Issue 1, 2012, Pages 71-77

  Kim, Mee Young ^a   Kim, Ok Ran ^a,b   Choi, Yong Seok ^a   Lee, Heuiran ^c   Park, Keerang ^d   Lee, Choon Taek ^e,f   Kang, Keon Wook ^e   Jeong, Sunjoo ^a  

^a Department of Molecular Biology   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d JS Gene Therapy R and D Center   (South Korea)

^e Seoul National University   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

Author keywords

Anti cancer therapeutic; Peptide; Tenascin C

Indexed keywords

ANTINEOPLASTIC AGENT; PEPTIDE; TENASCIN; TENASCIN C TARGETING PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN ISOLATION; PROTEIN TARGETING; SOLID TUMOR; TISSUE MICROARRAY; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GLIOBLASTOMA; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; TENASCIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863479633     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-012-2214-4     Document Type: Article

References (26)

1. Adams, M., Jones J. L., Walker, R. A., Pringle, J. H., and Bell, S. C. (2002). Changes in tenascin C isoform expression in invasive and preinvasive breast disease. Cancer Res. 62, 3289-3297. (Pubitemid 34602427)
2. Aggarwal, S., Singh, P., Topaloglu, O., Isaacs, J. T., and Denmeade, S. R. (2006). A dimeric peptide that binds selectively to prostatespecific membrane antigen and inhibits its enzymatic activity. Cancer Res. 66, 9171-9177. (Pubitemid 44521137)
3. 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J. Nucl. Med. 46, 1042-1051. (Pubitemid 43733522)
4. Bellofiore, P., Petronzelli, F., De Martino, T., Minenkova, O., Bombardi, V., Anastasi, A. M., Lindstedt, R., Felici, F., De Santis, R., and Verdoliva, A. (2006). Identification and refinement of a peptide affinity ligand with unique specificity for a monoclonal antitenascin C antibody by screening of a phage display library. J. Chromatogr. A 1107, 182-191. (Pubitemid 43184220)
5. Berndt, A., Anger, K., Richter, P., Borsi, L., Brack, S., Silacci, M., Franz, M., Wunderlich, H., Gajda, M., Zardi, L., et al. (2006). Differential expression of tenascin C splicing domains in urothelial carcinomas of the urinary bladder. J. Cancer Res. Clin. Oncol. 132, 537-546. (Pubitemid 43938338)
6. Brack, S. S., Silacci, M., Birchler, M., and Neri, D. (2006). Tumortargeting properties of novel antibodies specific to the large isoform of tenascin C. Clin. Cancer Res. 12, 3200-3208. (Pubitemid 43837370)
7. Chiquet-Ehrismann, R. (2004). Tenascins. Int. J. Biochem. Cell Biol. 36, 986-990. (Pubitemid 38501550)
8. Chiquet-Ehrismann, R., and Tucker, R. P. (2004). Connective tissues: signaling by tenascins. Int. J. Biochem. Cell Biol. 36, 1085-1089.
9. Fidler, I. J., Balasubramanian, K., Lin, Q., Kim, S. W., and Kim, S. (2010). The brain microenvironment and cancer metastasis. Mol. Cells 30, 93-98.
10. Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R., and Weitzman, M. D. (2001). Incorporation of tumortargeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975. (Pubitemid 32611306)
11. Hajitou, A., Pasqualini, R., and Arap, W. (2006). Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 16, 80-88.
12. Hicke, B. J., Marion, C., Chang, Y. F., Gould, T., Lynott, C. K., Parma, D., Schmidt, P. G., and Warren, S. (2001). Tenascin C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276, 48644-48654.
13. Hicke, B. J., Stephens, A. W., Gould, T., Chang, Y. F., Lynott, C. K., Heil, J., Borkowski, S., Hilger, C. S., Cook, G., Warren, S., et al. (2006). Tumor targeting by an aptamer. J. Nucl. Med. 47, 668-678. (Pubitemid 46768469)
14. Hsia, H. C., and Schwarzbauer, J. E. (2005). Meet the tenascins: multifunctional and mysterious. J. Biol. Chem. 280, 26641-26644. (Pubitemid 41040694)
15. Jäger, S., Jahnke, A., Wilmes, T., Adebahr, S., Vögtle, F. N., Delima-Hahn, E., Pfeifer, D., Berg, T., Lübbert, M., and Trepel, M. (2007). Leukemia targeting ligands isolated from phage display peptide libraries. Leukemia 21, 411-420.
16. Juuti, A., Nordling, S., Louhimo, J., Lundin, J., and Haglund, C. (2004). Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J. Clin. Pathol. 57, 1151-1155. (Pubitemid 39486519)
17. Khandare, J. J., and Minko, T. (2006). Antibodies and peptides in cancer therapy. Crit. Rev. Ther. Drug Carrier Syst. 23, 401-435. (Pubitemid 46524108)
18. Lee, S. M., Lee, E. J., Hong, H. Y., Kwon, M. K., Kwon, T. H., Choi, J. Y., Park, R. W., Kwon, T. G., Yoo, E. S., Yoon, G. S., et al. (2007). Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res. 5, 11-19.
19. Orend, G. (2005). Potential oncogenic action of tenascin C in tumorigenesis. Int. J. Biochem. Cell Biol. 37, 1066-1083. (Pubitemid 40311747)
20. Orend, G., and Chiquet-Ehrismann, R. (2006). Tenascin C induced signaling in cancer. Cancer Lett. 244, 143-163.
21. Rasmussen, U. B., Schreiber, V., Schultz, H., Mischler, F., and Schughart, K. (2002). Tumor cell-targeting by phage-displayed peptides. Cancer Gene Ther. 9, 606-612. (Pubitemid 34734425)
22. Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., Herndon, J. E. 2nd, Cokgor, I., McLendon, R. E., Pegram, C. N., Provenzale, J. M., et al. (2002). Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389-1397. (Pubitemid 34177447)
23. Silacci, M., Brack, S. S., Späth, N., Buck, A., Hillinger, S., Arni, S., Weder, W., Zardi, L., and Neri, D. (2006). Human monoclonal antibodies to domain C of tenascin C selectively target solid tumors in vivo. Protein Eng. Des. Sel. 19, 471-478. (Pubitemid 44408907)
24. Takeda, A., Otani, Y., Iseki, H., Takeuchi, H., Aikawa, K., Tabuchi, S., Shinozuka, N., Saeki, T., Okazaki, Y., and Koyama, I. (2007). Clinical significance of large tenascin C spliced variant as a potential biomarker for colorectal cancer. World J. Surg. 31, 388-394. (Pubitemid 46183528)
25. Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., and Massagué, J. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152.
26. White, S. J., Nicklin, S. A., Büning, H., Brosnan, M. J., Leike, K., Papadakis, E. D., Hallek, M., and Baker, A. H. (2004). Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-assocoated virus vectors. Circulation 109, 513-519. (Pubitemid 38168515)